The Venture Codex

Participated · Series D · Jan 2025

Qventus provides AI-based software that automates care operations across operating room and inpatient settings. The platform integrates with EHRs and leverages Generative AI, machine learning, and behavioral science to predict operational bottlenecks, recommend remedies, and automate processes. Its core offerings include Surgical Growth/Perioperative and Inpatient Capacity solutions that help care teams optimize patient flow and reduce cognitive load. In the last year its Inpatient Solution eliminated over 36,000 excess days for health system partners, saving them millions, and its Perioperative Solution generated $95M in annualized contribution margin in 2024 through Qventus-enabled cases. Led by CEO Mudit Garg and founded in 2012, the company intends to expand its AI Operational Assistants into new care settings beyond its current solutions. It plans to use recent funding to accelerate development and commercialization of those solutions. Qventus offers an AI-based SaaS platform purpose-built to automate care operations, integrating with EHRs and using AI, machine learning, and behavioral science. Its solutions target inpatient, perioperative, emergency department, and command center functions to improve operational workflows. The company partners with leading health systems, including Boston Medical Center, HonorHealth, M Health Fairview, Mercy, and Saint Luke’s Health System. Qventus is led by co-founder and CEO Mudit Garg and continues to expand its footprint across U.S. hospitals. Financially, the company recently attracted outside funding, including a $3M investment tied to prior growth financing announced in February 2022. Qventus provides AI-based software for care operations automation that integrates with EHRs. The platform uses AI, machine learning, and behavioral science to power practice solutions for inpatient, perioperative, emergency department, and command center settings. It partners with health systems including Boston Medical Center, HonorHealth, M Health Fairview, Mercy, and Saint Luke's Health System. Reported outcomes include fewer excess days, reductions in length of stay, and new cases added per operating room per month. The company is led by CEO Mudit Garg. Qventus plans to use the funding to expand its technology to additional hospitals and health systems across the United States. Qventus offers an AI/ML-driven software platform that streamlines and automates hospital workflows to improve flow, throughput and patient experience across emergency departments, perioperative areas, inpatient units, pharmacy and outpatient access. The platform acts as a “System of Action,” combining data, technology and people to enable real-time decision making and collaborative issue mitigation. Qventus provides modular capabilities for ED flow, perioperative scheduling, inpatient operations, patient safety and pharmacy operations. The company reports deployments at major U.S. health systems including NewYork-Presbyterian, Emory Healthcare and the Mercy health system, and its software has enabled more than 3.8M patient encounters to date. Qventus is based in Silicon Valley/Mountain View and plans to use new capital to continue rapid expansion of its AI-based platform across health systems. analyticsMD, based in Mountain View, CA and led by CEO Mudit Garg, provides an AI-powered hospital operations software platform. The platform collects large amounts of messy healthcare data, processes it in real time to predict issues and outcomes, and recommends immediate course-corrections that are sent to frontline teams. It addresses operational challenges across emergency departments, perioperative areas, inpatient and outpatient settings. The software is used by community, academic and public hospitals including Lucile Packard Children’s Hospital Stanford, El Camino Hospital, Sutter Auburn Faith Hospital, St. Joseph’s Medical Center, Medstar Montgomery Medical Center, Natividad Medical Center and Mercy. analyticsMD plans to use new funding for product development and to accelerate delivery of its AI platform to U.S. health systems.

Participated · Series A · Mar 2022

Altoida’s core product is a precision neurology platform that uses AI to analyze a proprietary 10-minute set of digital test activities delivered via augmented reality on a smartphone or tablet to capture cognitive and functional changes. The AR-based tests simulate activities of daily living to detect Mild Cognitive Impairment and Alzheimer’s earlier and more accurately than existing methods; the platform has received FDA Breakthrough Device Designation. The company says its technology is intended to accelerate and improve drug development, research, and clinical care for neurological diseases and to validate applications across Parkinson’s and schizophrenia. Altoida plans to invest in medical, scientific, engineering, and commercial teams, and to expand its US and global intellectual property and regulatory portfolios. The platform is supported by more than 20 years of scientific research and aims to address the large and growing global burden of Alzheimer’s and related dementias. Altoida is based in Washington, D.C. Altoida develops an FDA-cleared and CE Mark–approved medical device and brain health data platform that uses AI, ML and AR to collect functional and cognitive digital biomarkers. The company leverages smart device sensors and interactive tasks (asking patients to hide and seek virtual objects) to analyze visuospatial and executive function and detect ‘‘micro-errors’’ as prognostic and diagnostic biomarkers. Altoida’s technology is used by researchers, patients and physicians to detect Mild Cognitive Impairment due to Alzheimer’s disease in patients 62+ years old between six and ten years prior to symptom onset. The platform and methodology have been validated in more than 12 peer-reviewed publications and over 200 independent studies. Altoida says the new financing will support expansion in the US, Japan, Europe and Brazil. The company is led by Dr. Richard Fischer and has offices in Houston, San Diego and Lucerne, Switzerland. Altoida develops an FDA-cleared and CE Mark-approved medical device and brain-health data platform that objectively assesses cognitive and everyday functions prior to symptom onset. Its product leverages artificial intelligence, machine learning and augmented reality to collect functional and cognitive biomarkers. The platform analyzes visuospatial and executive function through a battery of three tests that ask patients to hide and seek virtual objects in physical space. Altoida has been validated in more than 12 peer-reviewed publications and over 200 independent studies and is used in clinics across the US, Europe and Brazil. The company raised $6.3M in a Series A and intends to use the capital to expand its global presence with an immediate focus on commercialization in the US and EU markets. Altoida maintains offices in Houston, San Diego and Lucerne, Switzerland.

Participated · Seed · Mar 2021

CND Life Sciences develops objective biomarker-based diagnostics for neurodegenerative diseases and is best known for the Syn-One Test, a proprietary skin biopsy-based LDT designed to detect phosphorylated alpha-synuclein and other pathological markers. Since 2020, Syn-One has been ordered by more than 4,000 neurologists and clinicians to support diagnostic evaluations for over 60,000 patients, and it is supported by a growing body of peer-reviewed clinical evidence. The company collaborates with biopharmaceutical firms on clinical trials and conducts studies on early disease detection and synuclein quantification. CND is positioning Syn-One as part of a broader multimodal biomarker capability to aid diagnosis, disease characterization, and earlier intervention. Financially, the company recently secured growth financing led by S-Curve Partners to support commercial growth, product innovation, strategic partnerships, and expanded access to its platform.

Participated · Equity · Oct 2020

NeoLight makes hospital‑grade phototherapy hardware intended to treat neonatal jaundice, a condition affecting roughly 60% of newborns. The company originally designed its devices for hospital use but pivoted to market the hardware to new parents. The pivot responds to trends toward earlier newborn discharge and home quarantine, when doctors may not know if treatment is necessary until three or four days after birth. NeoLight’s therapies aim to offer clinical-grade treatment at home to prevent bilirubin-related brain damage. Founder Vivek Kopparthi has described the timing gap between discharge and detection of treatment need as a core challenge the product addresses. The company recently secured additional financing to support this consumer-facing push.